MarketCap
Teleflex Incorporated TFX
$ 139.67
1.42%
Facebook
X
Telegram
Teleflex Incorporated Revenue | TFX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Teleflex Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 569 M | 442 M | 1.71 B | 2.79 B | 2.81 B | 2.54 B | 2.6 B | 2.45 B | 2.15 B | 1.87 B | 1.81 B | 1.84 B | 1.7 B | 1.55 B | 1.53 B | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.81 B | 442 M | 1.89 B |
Quarterly Revenue Teleflex Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 570 M | 548 M | 913 M | 781 M | 701 M | 764 M | 750 M | 738 M | 746 M | 743 M | 711 M | - | 687 M | 705 M | 642 M | - | 700 M | 713 M | 634 M | 711 M | 628 M | 567 M | 631 M | 681 M | 648 M | 653 M | 614 M | 642 M | 610 M | 610 M | 587 M | 595 M | 535 M | 529 M | 488 M | 514 M | 456 M | 474 M | 425 M | 485 M | 444 M | 452 M | 429 M | 476 M | 457 M | 468 M | 439 M | 451 M | 414 M | 420 M | 412 M | 419 M | 368 M | 383 M | 381 M | 403 M | 363 M | 381 M | 354 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 913 M | 354 M | 562 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
96.2 M | $ 36.38 | 0.54 % | $ 1.74 B |  USA |
 |
Ekso Bionics Holdings
EKSO
|
71.6 M | - | - | $ 28.6 M | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 71.17 | 0.3 % | $ 14.2 B | USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 90.49 | 1.06 % | $ 5.35 B | USA |
 |
AtriCure
ATRC
|
535 M | $ 48.54 | 2.28 % | $ 2.32 B | USA |
 |
Nephros
NEPH
|
18.8 M | $ 4.55 | 5.57 % | $ 48.3 M | USA |
 |
Haemonetics Corporation
HAE
|
1.33 B | $ 103.96 | 0.03 % | $ 4.9 B | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |
 |
Glaukos Corporation
GKOS
|
507 M | $ 179.87 | 0.74 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
86.6 M | $ 7.93 | 0.38 % | $ 352 M | USA |
 |
AngioDynamics
ANGO
|
320 M | $ 15.85 | 0.44 % | $ 658 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 175.1 | 0.43 % | $ 4.31 B | USA |
 |
InfuSystem Holdings
INFU
|
143 M | $ 12.04 | 0.12 % | $ 249 M | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 120.25 | 3.37 % | $ 3.85 B | USA |
 |
STERIS plc
STE
|
5.94 B | $ 233.78 | 0.35 % | $ 23 B | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 62.56 | 1.6 % | $ 206 B | USA |
 |
Baxter International
BAX
|
11.2 B | $ 26.13 | 0.81 % | $ 13.4 B | USA |
 |
Repligen Corporation
RGEN
|
738 M | $ 176.27 | 0.96 % | $ 9.91 M | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 47.57 | 0.04 % | $ 3.21 B | USA |
 |
ResMed
RMD
|
5.65 B | $ 240.33 | 1.94 % | $ 35 B | USA |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 372.6 | 1.51 % | $ 133 B | USA |
 |
electroCore
ECOR
|
32 M | $ 9.63 | 1.54 % | $ 81.7 K | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.12 | 0.72 % | $ 2.22 B | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.5 | 0.36 % | $ 41 M | USA |
 |
Alcon
ALC
|
10.4 B | $ 72.01 | 0.07 % | $ 35.5 B |  Schweiz |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 337.47 | 0.11 % | $ 24.4 B | USA |
 |
Envista Holdings Corporation
NVST
|
2.72 B | $ 27.13 | 0.02 % | $ 4.56 B | USA |
 |
Masimo Corporation
MASI
|
2.09 B | - | - | $ 9.59 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.48 | 0.33 % | $ 67.8 M |  Israel |
 |
STAAR Surgical Company
STAA
|
239 M | $ 22.11 | 0.09 % | $ 1.1 B | USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.45 | 0.34 % | $ 132 M | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 3.23 | 0.94 % | $ 149 M | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 3.6 | 0.13 % | $ 265 M | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 80.45 | 0.99 % | $ 1.82 B | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 189.52 | 0.74 % | $ 54.5 B | USA |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.73 | 1.14 % | $ 21.9 M | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 72.77 | 1.35 % | $ 236 M | USA |